313 related articles for article (PubMed ID: 29690749)
1. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
Lee SH; Lee B; Shim JH; Lee KW; Yun JW; Kim SY; Kim TY; Kim YH; Ko YH; Chung HC; Yu CS; Lee J; Rha SY; Kim TW; Jung KH; Im SA; Moon HG; Cho S; Kang JH; Kim J; Kim SK; Ryu HS; Ha SY; Kim JI; Chung YJ; Kim C; Kim HL; Park WY; Noh DY; Park K
Cancer Res Treat; 2019 Jan; 51(1):211-222. PubMed ID: 29690749
[TBL] [Abstract][Full Text] [Related]
2. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
3. Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Park HS; Lim SM; Kim S; Kim S; Kim HR; Kwack K; Lee MG; Kim JH; Moon YW
PLoS One; 2016; 11(4):e0154133. PubMed ID: 27105424
[TBL] [Abstract][Full Text] [Related]
4. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
[TBL] [Abstract][Full Text] [Related]
5. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.
Hedegaard J; Thorsen K; Lund MK; Hein AM; Hamilton-Dutoit SJ; Vang S; Nordentoft I; Birkenkamp-Demtröder K; Kruhøffer M; Hager H; Knudsen B; Andersen CL; Sørensen KD; Pedersen JS; Ørntoft TF; Dyrskjøt L
PLoS One; 2014; 9(5):e98187. PubMed ID: 24878701
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
9. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
[TBL] [Abstract][Full Text] [Related]
10. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.
De Paoli-Iseppi R; Johansson PA; Menzies AM; Dias KR; Pupo GM; Kakavand H; Wilmott JS; Mann GJ; Hayward NK; Dinger ME; Long GV; Scolyer RA
Pathology; 2016 Apr; 48(3):261-6. PubMed ID: 27020503
[TBL] [Abstract][Full Text] [Related]
11. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
[TBL] [Abstract][Full Text] [Related]
12. Robustness of Next Generation Sequencing on Older Formalin-Fixed Paraffin-Embedded Tissue.
Carrick DM; Mehaffey MG; Sachs MC; Altekruse S; Camalier C; Chuaqui R; Cozen W; Das B; Hernandez BY; Lih CJ; Lynch CF; Makhlouf H; McGregor P; McShane LM; Phillips Rohan J; Walsh WD; Williams PM; Gillanders EM; Mechanic LE; Schully SD
PLoS One; 2015; 10(7):e0127353. PubMed ID: 26222067
[TBL] [Abstract][Full Text] [Related]
13. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
[TBL] [Abstract][Full Text] [Related]
14. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
[TBL] [Abstract][Full Text] [Related]
15. Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing.
Nagahashi M; Shimada Y; Ichikawa H; Nakagawa S; Sato N; Kaneko K; Homma K; Kawasaki T; Kodama K; Lyle S; Takabe K; Wakai T
J Surg Res; 2017 Dec; 220():125-132. PubMed ID: 29180174
[TBL] [Abstract][Full Text] [Related]
16. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
17. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
18. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.
Wagle N; Berger MF; Davis MJ; Blumenstiel B; Defelice M; Pochanard P; Ducar M; Van Hummelen P; Macconaill LE; Hahn WC; Meyerson M; Gabriel SB; Garraway LA
Cancer Discov; 2012 Jan; 2(1):82-93. PubMed ID: 22585170
[TBL] [Abstract][Full Text] [Related]
19. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
20. High-throughput detection of clinically targetable alterations using next-generation sequencing.
Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
